23121-10-0

Upstream product

• 4892-02-8 Methyl thiosalicylate 
• 37527-69-8 (2-ethylsulfanyl-phenyl)-methanol 
• 3795-78-6 2-ethylsulfanyl-benzoic acid methyl ester 
• 23010-33-5 1-(chloromethyl)-2-(ethylsulfanyl)benzene 

Downstream Products

• 1352128-46-1 8-(2-ethanesulfonyl-benzyl)-2-methylsulfanyl-8H-pyrido[2,3-d]-pyrimidin-7-one 
• 1352128-48-3 6-bromo-8-(2-ethanesulfonyl-benzyl)-2-methylsulfanyl-8H-pyrido[2,3-d]pyrimidin-7-one 
• 1352128-14-3 8-(2-ethanesulfonyl-benzyl)-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one 
• 1352128-49-4 6-bromo-8-(2-ethanesulfonylbenzyl)-2-methanesulfinyl-8H-pyrido[2,3-d]pyrimidin-7-one 
• 1352128-50-7 6-bromo-8-(2-ethanesulfonylbenzyl)-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one 
• 1352128-17-6 8-(2-ethanesulfonylbenzyl)-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-6-phenyl-8H-pyrido[2,3-d]pyrimidin-7-one 

Relevant academic research and scientific papers

PAK INHIBITORS FOR THE TREATMENT OF CANCER

Provided herein are methods of utilizing PAK inhibitors for the treatment of cancer. Further provided herein are compounds and formulations utilized for the treatment of cancer.

8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS

Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders.